A genome-wide association study has identified the first risk factors for sporadic prion disease other than mutations of PRNP, which encodes prion protein. These hits could open up new fronts in prion biology, risk prediction, and drug development.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jones, E. et al. Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol. 19, 840–848 (2020).
Tabrizi, S. J., Flower, M. D., Ross, C. A. & Wild, E. J. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat. Rev. Neurol. 16, 529–546 (2020).
Fahed, A. C. et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat. Commun. 11, 3635 (2020).
Minikel, E. V. et al. Quantifying prion disease penetrance using large population control cohorts. Sci. Transl Med. 8, 322ra9 (2016).
Minikel, E. V. et al. Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology 93, e125–e134 (2019).
Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
Leonenko, G. et al. Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition. Ann. Neurol. 86, 427–435 (2019).
Minikel, E. V. et al. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res. https://doi.org/10.1093/nar/gkaa616 (2020).
Vallabh, S. M., Minikel, E. V., Schreiber, S. L. & Lander, E. S. Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurol. 19, 361–368 (2020).
Mok, T. H. & Mead, S. Preclinical biomarkers of prion infection and neurodegeneration. Curr. Opin. Neurobiol. 61, 82–88 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.M.V. has received speaking fees from Biogen and Illumina, and has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals. E.V.M. has received consulting fees from Deerfield Management and Guidepoint, and has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Vallabh, S.M., Minikel, E.V. Implications of new genetic risk factors in prion disease. Nat Rev Neurol 17, 5–6 (2021). https://doi.org/10.1038/s41582-020-00433-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-020-00433-0